Abstract
Using L1210 and a subline resistance to chloroethylnitrosoureas (L1210/BCNU), we found that the resistance to 1-(2-chloroethyl)-1-nitrosourea (CNU) or to diethyl-1-3-(2-chloroethyl)-3-nitrosoureido ethyl phosphonate (fotemustine) can be reversed by a pretreatment with O6-methyl Guanine (O6-mGua) or temozolomide. In L1210/BCNU but not in L1210 the pretreatment with O6mGua caused an increased peak level of CNU-induced DNA-interstrand crosslinks. We then evaluated whether the resistance to BCNU could be counteracted in vivo by i.p. O6mGua treatment of L1210/BCNU bearing mice. The results were negative due to the fact that O6mGua, which was not toxic when given alone, caused a high toxicity when associated with BCNU.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Carmustine / pharmacology*
-
Carmustine / therapeutic use
-
Cell Cycle / drug effects
-
Cell Division / drug effects
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / pharmacology
-
Dacarbazine / therapeutic use
-
Drug Evaluation, Preclinical
-
Drug Resistance
-
Ethylnitrosourea / analogs & derivatives*
-
Ethylnitrosourea / pharmacology
-
Ethylnitrosourea / therapeutic use
-
Guanine / analogs & derivatives*
-
Guanine / pharmacology
-
Guanine / therapeutic use
-
Kinetics
-
Leukemia L1210 / drug therapy*
-
Mice
-
Mice, Inbred DBA
-
Nitrosourea Compounds / pharmacology*
-
Nitrosourea Compounds / therapeutic use
-
Organophosphorus Compounds / pharmacology*
-
Organophosphorus Compounds / therapeutic use
-
Temozolomide
Substances
-
Antineoplastic Agents
-
Nitrosourea Compounds
-
Organophosphorus Compounds
-
1-(2-chloroethyl)-1-nitrosourea
-
Guanine
-
Dacarbazine
-
O-(6)-methylguanine
-
fotemustine
-
Ethylnitrosourea
-
Carmustine
-
Temozolomide